Senator John Fetterman explains how GLP-1 drugs changed his life

A U.S.senator said a GLP-1 drug changed his life — and now he’s calling for widespread access to anti-obesity medications.In a New York Times op-ed on April 8, Sen.

John Fetterman, D-Pa., wrote about his experience with Mounjaro (tirzepatide).The injectable prescription medicine is primarily used to treat type 2 diabetes. Fetterman was prescribed the medication in July 2024.“As a stroke survivor, I was interested in studies showing [Mounjaro] could significantly reduce the risk of major cardiac events,” the senator wrote.“Even though I started taking it for my heart health, I’ve been struck by how much better it has made me feel across the board.It’s made a significant impact on my overall health,” he continued. “Aches, pains and stiffness have vanished.

Physically, I feel a decade younger, as well as clearer-headed and more optimistic than I’d been in years.As far as side effects, I’ve also lost around 20 pounds.”Beyond lowering blood sugar, GLP-1 medications have also been linked to a range of other benefits, including improved heart health, neurological function and metabolic health, as Fox News Digital has reported.Eli Lilly, maker of Mounjaro, also offers another version of the drug called Zepbound, which is the same medication approved for weight loss, chronic weight management and sleep apnea. Other GLP-1 medications include Ozempic, Wegovy, Victoza, Saxenda, all made by Novo Nordisk.Fetterman noted that GLP-1 drugs have been found to have beneficial effects on cholesterol, heart rate and heart inflammation. “Some recent studies suggest they might even help curb alcohol addiction and support cognitive function, potentially slowing or preventing conditions like Parkinson’s and Alzheimer’s,” he wrote in the Times op-ed.In the op-ed, Fetterman called for expanded access to these medications, which can cost up to $1,000 out of pocket if not covered by insurance.“Currently, Medicare covers these drugs only under speci...